Onconetix, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
Onconetix, Inc. (ONCO) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $57 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-03-13
- Onconetix, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was $57.00, a 99.80% decline from fiscal 2024.
- Onconetix, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $29.09K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $57.00 10-K · filed 2026-03-13 |
| 2024-12-31 | $29.09K 10-K · filed 2026-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |